Literature DB >> 20637732

Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics.

Mathilde Bayet-Robert1, Suzanne Lim, Chantal Barthomeuf, Daniel Morvan.   

Abstract

Marine plants and animals are sources of a huge number of pharmacologically active compounds, some of which exhibit antineoplastic activity of clinical relevance. However the mechanism of action of marine natural products (MNPs) is poorly understood. In this study, proton NMR spectroscopy-based metabolomics was applied to unravel biochemical disorders induced in human MCF7 breast cancer cells by 3 lead candidate anticancer MNPs: ascididemin (Asc), lamellarin-D (Lam-D), and kahalalide F (KF). Asc, Lam-D, and KF provoked a severe decrease in DNA content in MCF7 cells after 24-h treatment. Asc and Lam-D provoked apoptosis, whereas KF induced non-apoptotic cell death. Metabolite profiling revealed major biochemical disorders following treatment. The response of MCF7 tumor cells to Asc involved the accumulation of citrate (x17 the control level, P<0.001), testifying enzyme blockade in citrate metabolism, and the accumulation of gluconate (x9.8, P<0.005), a metabolite never reported at such concentration in tumor cells, probably testifying glycolysis shutdown. The response to Lam-D involved the accumulation of aspartate (x7.2, P<0.05), glutamate (x14.7, P<0.05), and lactate (x2.3, P<0.05), probably in relation with the targeting of the malate-aspartate shuttle, as discussed. The response to KF involved increased lipid accumulation (polyunsaturated fatty acids x9.8, P<0.05), and phospholipid and acetate derivative alterations. Altogether, this study demonstrates the potential of proton NMR spectroscopy-based metabolomics to help uncover metabolic targets and elucidate the mechanism of cytotoxicity of candidate antineoplastic MNPs. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637732     DOI: 10.1016/j.bcp.2010.07.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil.

Authors:  Shinsuke Sasada; Yoshihiro Miyata; Yasuhiro Tsutani; Naohiro Tsuyama; Tsutomu Masujima; Jun Hihara; Morihito Okada
Journal:  Oncol Rep       Date:  2012-12-11       Impact factor: 3.906

2.  The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?

Authors:  Marie S A Palmnas; Hans J Vogel
Journal:  Metabolites       Date:  2013-05-17

3.  Functional metabolomics uncovers metabolic alterations associated to severe oxidative stress in MCF7 breast cancer cells exposed to ascididemin.

Authors:  Daniel Morvan
Journal:  Mar Drugs       Date:  2013-10-11       Impact factor: 5.118

Review 4.  Anticancer properties of lamellarins.

Authors:  Christian Bailly
Journal:  Mar Drugs       Date:  2015-02-19       Impact factor: 5.118

Review 5.  Synthetic approaches to the lamellarins--a comprehensive review.

Authors:  Dennis Imbri; Johannes Tauber; Till Opatz
Journal:  Mar Drugs       Date:  2014-12-18       Impact factor: 5.118

Review 6.  Metabolomics on the study of marine organisms.

Authors:  Lina M Bayona; Nicole J de Voogd; Young Hae Choi
Journal:  Metabolomics       Date:  2022-03-02       Impact factor: 4.290

Review 7.  Recent advances and limitations in the application of kahalalides for the control of cancer.

Authors:  Scott Wyer; Danyelle M Townsend; Zhiwei Ye; Antonis Kourtidis; Yeun-Mun Choo; André Luís Branco de Barros; Mohamed S Donia; Mark T Hamann
Journal:  Biomed Pharmacother       Date:  2022-02-08       Impact factor: 6.529

8.  Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel.

Authors:  Mathilde Bayet-Robert; Daniel Morvan
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.